Wnt5a expression and prognosis in stage II–III colon cancer
| Autor: | Anne Dyhl-Polk, D.L. Nielsen, Cecilia Margareta Lund, Lene Riis |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
Oncology Cancer Research medicine.medical_specialty Colorectal cancer lcsh:RC254-282 Metastasis 03 medical and health sciences 0302 clinical medicine Prostate Internal medicine medicine Overall survival Disease free survival Original Research Performance status biology business.industry Cancer Wnt5a medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens Staining Colon cancer body regions 030104 developmental biology medicine.anatomical_structure 030220 oncology & carcinogenesis embryonic structures biology.protein Immunohistochemistry sense organs Antibody business |
| Zdroj: | Translational Oncology, Vol 14, Iss 1, Pp 100892-(2021) Translational Oncology Lund, C M, Dyhl-Polk, A, Nielsen, D L & Riis, L B 2021, ' Wnt5a expression and prognosis in stage II–III colon cancer ', Translational Oncology, vol. 14, no. 1, 100892 . https://doi.org/10.1016/j.tranon.2020.100892 |
| ISSN: | 1936-5233 |
| Popis: | Cancer metastases accounts for most cancer deaths. The secreting glycoprotein Wnt5a impairs tumor cell migration and reduces invasiveness and metastasis. High Wnt5a expression in tumor cells is correlated to better outcomes in patients with breast, prostate and epithelial ovarian cancer. We aimed to investigate the association between the Wnt5a expression and outcomes in patients with colon cancer (CC) stage II/III. We performed a retrospective single-center study evaluating 345 patients with radical resection for primary CC, stage II/III, who started 6 months of adjuvant chemotherapy with 5-FU or capecitabine ± oxaliplatin between 2001 and 2015. Archived formalin-fixed paraffin embedded tumor tissue from resection specimens were stained with Wnt5a antibody using immunohistochemistry. Cytoplasmatic Wnt5a staining was assessed according to intensity and percentage of stained cells. Patients were divided in groups depending on high (n = 230) or low (n = 115) Wnt5a expression. Disease free survival (DFS) and overall survival (OS) were analyzed for the two groups using Kaplan-Meier plots and Long rank test. Patients with Wnt5a-negative tumors had significantly poorer performance status (PS) than patients with high Wnt5a expression (p = 0.046). No significant difference was seen between patients with low and high Wnt5a expression in terms of 5-year DFS (p = 0.517) or 5-year OS (p = 0.415). Poor PS was associated with lower DFS (p = 0.002) and OS (p Highlights • High expression of Wnt5a in tumor cells are correlated to significantly better outcomes in patients with different cancers. • We found no difference in survival among patients with colon cancer stage II-III depending on their Wnt5a expression. • Patients with low Wnt5a expression had significantly poor performance status than patients with high levels. • Poor performance status was shown to predict poorer outcomes. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|